Thursday, 18 April 2024

[the_ad_group id="2845"]


Beam Therapeutics CFO sells shares worth over $174k By

Beam Therapeutics CFO sells shares worth over $174k By

[the_ad id="21475"]


Beam Therapeutics Inc. (NASDAQ:BEAM) has reported a significant transaction involving its Chief Financial Officer, Terry-Ann Burrell. According to the latest SEC filing, Burrell sold 5,446 shares of the company’s common stock on April 1, 2024, for a total value exceeding $174,925.

The shares were sold at a weighted average price of $32.12, with individual transactions occurring within a price range of $32.10 to $32.18. This sale was conducted automatically under a Rule 10b5-1 trading plan, which Burrell had previously established on May 19, 2023. The plan is designed to allow insiders to sell their shares at predetermined times and prices, thus preventing any accusations of trading on non-public, material information.

The transaction was executed to cover tax withholding obligations related to the vesting of certain restricted stock units granted to Burrell under Beam Therapeutics’ 2019 Equity Incentive Plan. These units vested on March 31 of the years 2021, 2022, and 2023.

Following this sale, Terry-Ann Burrell still holds a substantial number of shares in Beam Therapeutics, with a total of 70,137 shares remaining in her possession. The company, which specializes in biological products and operates out of Cambridge, Massachusetts, has not made any additional comments regarding this transaction.

Investors and followers of Beam Therapeutics will be keeping a close eye on the company’s stock performance and any further insider trading activity to gauge the confidence level of its executives and their outlook on the company’s future.

InvestingPro Insights

Beam Therapeutics Inc. (NASDAQ:BEAM) has been the subject of investor attention following a notable insider transaction by its CFO. The company’s financial metrics provide a broader context for understanding its market position. With an adjusted market capitalization of $2.34 billion, Beam’s scale in the biotech industry is noteworthy. Despite the company’s negative earnings figures, with a P/E ratio of -17.34 and an adjusted P/E ratio for the last twelve months as of Q4 2023 at -19.25, investors are likely considering the company’s growth potential and future profitability.

The company’s revenue growth has been extraordinary, with a 520.01% increase over the last twelve months as of Q4 2023, and a staggering quarterly revenue growth of 1478.04% in Q4 2023. This explosive growth rate may be a key factor for investors assessing the company’s long-term value. However, it’s important to note the negative…

Click Here to Read the Full Original Article at All News…


[the_ad id="21476"]